Challenges in the Development of High Protein Concentration Formulations-Reference-Cited by-同舟云学术

Challenges in the Development of High Protein Concentration Formulations

Published:2009-10-10 Issue: Volume: Page:131-147
ISSN:
Container-title:Current Trends in Monoclonal Antibody Development and Manufacturing
language:
Short-container-title:

Author:

Shire Steven J.,Shahrokh Zahra,Liu Jun

Publisher

Springer New York

Link

http://link.springer.com/content/pdf/10.1007/978-0-387-76643-0_9

Reference71 articles.

1. Ahern TJ, Manning MC (eds) (1992) Stability of protein pharmaceuticals. Part A: Chemical and physical pathways of protein degradation. Plenum, New York, p 434

2. Andya JD, Hsu CC, Shire SJ (2003) Mechanisms of aggregate formation and carbohydrate excipient stabilization of lyophilized humanized monoclonal antibody formulations. AAPS PharmSci 5(2):E10

3. Arakawa T, Timasheff SN (1982) Stabilization of protein structure by sugars. Biochemistry 21:6536–6544

4. Arakawa T, Timasheff SN (1985) Theory of protein solubility. Methods Enzymol 114:49–77

5. Arakawa T, Kita Y, Carpenter JF (1991) Protein–solvent interactions in pharmaceutical formulations. Pharm Res 8(3):285–291

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Computational Procedure for Predicting Excipient Effects on Protein–Protein Affinities;Journal of Chemical Theory and Computation;2024-01-31

2. A computational procedure for predicting excipient effects on protein-protein affinities;2023-12-23

3. Biophysical Determinants for the Viscosity of Concentrated Monoclonal Antibody Solutions;Molecular Pharmaceutics;2023-08-07

4. A systematic review of commercial high concentration antibody drug products approved in the US: formulation composition, dosage form design and primary packaging considerations;mAbs;2023-05-27

5. Stability of a high-concentration monoclonal antibody solution produced by liquid–liquid phase separation;mAbs;2021-01-01